Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting

Overview

This purpose of this study is to evaluate the efficacy and safety of single and repeated doses of palonosetron hydrochloride in preventing nausea and vomiting caused by moderate and highly emetogenic chemotherapy in patients.

Full Title of Study: “A Multi-center, Stratified Randomized, Controlled Study to Evaluate the Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in China”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2012

Detailed Description

Group I (Highly Emetogenic Chemotherapy): Patients that accepted chemotherapy including Cisplatin≥50mg/m2, Carmustine>250mg/m2, Cyclophosphamide>1500mg/m2, Dacarbazine>60mg/m2, Doxorubicin>60mg/m2, Epirubicin>90mg/m2, IFO≥10g/m2 or AC program. Group II (Moderately Emetogenic Chemotherapy): Patients that accepted chemotherapy including any dose of Carboplatin, Daunorubicin, Oaliplatin, Irinotecan, or Doxorubicin<60mg/m2(not include liposomal doxorubicin), Epirubicin≤90mg/m2, Carmustine≤250mg/m2, Methotrexate≥250mg/m2, Cyclophosphamide≤1500mg/m2, Arabinoside>200mg/m2, IFO<10g/m2, Cisplatin≥50mg/m2. Total subjects: 1000, single dose of palonosetron group of 500 patients, repeated doses of palonosetron group of 500 patients. According to the study subjects receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy, subjects are stratified randomize.

Interventions

  • Drug: Palonosetron Hydrochloride
    • 0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
  • Drug: Palonosetron Hydrochloride
    • 0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.

Arms, Groups and Cohorts

  • Active Comparator: H PALO day 1
    • Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
  • Experimental: H PALO day 1,3,5
    • Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
  • Active Comparator: M PALO day 1
    • Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
  • Experimental: M PALO day 1,3,5
    • Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5

Clinical Trial Outcome Measures

Primary Measures

  • Complete Response rate
    • Time Frame: 2-7 days
    • defined as no emetic episode and no use of rescue medication

Secondary Measures

  • Complete Response rate
    • Time Frame: 0-24 hours, 0-7 days
    • defined as no emetic episode and no use of rescue medication

Participating in This Clinical Trial

Inclusion Criteria

1. Patients candidates to a chemotherapy treatment, with histologically or cytologically confirmed malignant disease; 2. The concrete chemotherapy plan does not limited, group I (Highly Emetogenic Chemotherapy), group II (Moderately Emetogenic Chemotherapy); 3. Male or female aged 18-75 years, ECOG≤2, estimates survival time≥3 months; 4. WBC≥3.0×109/L, ANC≥1.5×109/L, PLT≥80×109/L, total bilirubin≤1.5×ULN(Normal value upper limit), AST and ALT≤2.5×ULN(With transferability liver cancer≤5×ULN), Cr and BUN≤1.5×ULN, electrolyte and electrocardiogram are normal, conforms to the chemotherapy adaptation; 5. Patients have been apart from the previous chemotherapy to finish above 2 weeks (including 2 weeks); 6. Patients that voluntarily sign the consent form. Exclusion Criteria:

1. Pregnancy, or patients during breast feeding; 2. Patients have accepted any radiotherapy during the experimental period; 3. Gastric outlet or intestinal obstruction; 4. Patients have serious heart diseases, liver kidney diseases, or metabolism function disorder; 5. Patients have epilepsy, or have been used psychotropic drug and calm drug; 6. Received any drugs with potential anti-emetic efficacy, or experienced any vomiting, nausea or retching in the 24 hours prior to chemotherapy; 7. Patients with transferability brain tumor, have vomiting caused by skull high pressure, or can not speak sickness situation and adverse reactions by self; 8. Patients have known hypersensitivity to 5-HT3 antagonists; 9. Patients have chemotherapy contraindications; 10. Patients are participating, or have participated in other Clinical studies of new drugs within 2 weeks.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shanghai Changzheng Hospital
  • Collaborator
    • JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd
  • Provider of Information About this Clinical Study
    • Principal Investigator: Zhan Wang, Principal Investigator – Shanghai Changzheng Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.